A cocktail therapeutic strategy based on clofarabine-containing aptamer-PROTAC for enhanced cancer therapy.

Zhenzhen ChenMohan ChenRan Liu Huanhuan Fan Jingjing Zhang

Published in: Chemical communications (Cambridge, England) (2023)

By introducing a therapeutic nucleoside analogue tail to the parent Aptamer-PROTACs, a PROTAC-cocktail system (ApTCs-3X) was designed and evaluated. ApTCs-3X exhibited improved nuclease resistance and efficiently degraded target protein with subcellular localization preference. This cocktail therapy results in enhanced therapeutic outcomes, making it suitable for advancing PROTAC in combination therapy.

Keyphrases

combination therapy
cancer therapy
gold nanoparticles
sensitive detection
drug delivery
stem cells
metabolic syndrome
mesenchymal stem cells
adipose tissue
transcription factor
binding protein
dna binding
magnetic nanoparticles
cell therapy
bone marrow